These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26393949)

  • 1. Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.
    Kazmierczak PM; Burian E; Eschbach R; Hirner-Eppeneder H; Moser M; Havla L; Eisenblätter M; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(9):e0138452. PubMed ID: 26393949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.
    Eschbach RS; Fendler WP; Kazmierczak PM; Hacker M; Rominger A; Carlsen J; Hirner-Eppeneder H; Schuster J; Moser M; Havla L; Schneider MJ; Ingrisch M; Spaeth L; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(2):e0115543. PubMed ID: 25668193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
    Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
    PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation.
    Cyran CC; Kazmierczak PM; Hirner H; Moser M; Ingrisch M; Havla L; Michels A; Eschbach R; Schwarz B; Reiser MF; Bruns CJ; Nikolaou K
    PLoS One; 2013; 8(9):e76009. PubMed ID: 24098755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring early response to anti-angiogenic therapy: diffusion-weighted magnetic resonance imaging and volume measurements in colon carcinoma xenografts.
    Schneider MJ; Cyran CC; Nikolaou K; Hirner H; Reiser MF; Dietrich O
    PLoS One; 2014; 9(9):e106970. PubMed ID: 25222284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer.
    Kazmierczak PM; Todica A; Gildehaus FJ; Hirner-Eppeneder H; Brendel M; Eschbach RS; Hellmann M; Nikolaou K; Reiser MF; Wester HJ; Kropf S; Rominger A; Cyran CC
    PLoS One; 2016; 11(12):e0168248. PubMed ID: 27992512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
    Sterzik A; Paprottka PM; Zengel P; Hirner H; Roßpunt S; Eschbach R; Moser M; Havla L; Ingrisch M; Mack B; Reiser MF; Nikolaou K; Cyran CC
    Acta Radiol; 2015 Mar; 56(3):294-303. PubMed ID: 24609871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Lysis Syndrome in Metastatic Colon Cancer Following Treatment with Regorafenib.
    Farooqi B; Simmons J; Hao Z
    J Gastrointest Cancer; 2015 Sep; 46(3):314-6. PubMed ID: 25859838
    [No Abstract]   [Full Text] [Related]  

  • 13. Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics.
    Jost G; Pietsch H; Grenacher L
    Invest Radiol; 2013 Oct; 48(10):715-21. PubMed ID: 23666093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The malignant progression effects of regorafenib in human colon cancer cells.
    Tomida C; Aibara K; Yamagishi N; Yano C; Nagano H; Abe T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
    J Med Invest; 2015; 62(3-4):195-8. PubMed ID: 26399347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
    Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
    J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and
    Gross J; Palmowski K; Doleschel D; Rix A; Gremse F; Verburg F; Mottaghy FM; Kiessling F; Lederle W; Palmowski M
    Contrast Media Mol Imaging; 2021; 2021():6676337. PubMed ID: 34007252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parameters of dynamic contrast-enhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer.
    Li L; Wang K; Sun X; Wang K; Sun Y; Zhang G; Shen B
    Med Sci Monit; 2015 Feb; 21():376-82. PubMed ID: 25640082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
    Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
    Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.